Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

IMUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of a ...

Shares of IMUNON are trading higher Wednesday morning. The company announced a clinical milestone for its lead drug candidate ...

Imunon, Inc. (($IMNN)) has held its Q2 earnings call. Read on for the main highlights of the call. The recent earnings call for Imunon, Inc.

The current quarter introduced the 15% onetime stock dividend and confirmed accelerated site activation for OVATION 3, compared to the previous quarter's focus on initial site readiness and ...

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer Initiation of additional trial sites and patient enrollment activities ...

(Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

IMUNON, Inc. announced a successful Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the FDA, which aligns their production strategy for IMNN-001, a DNA-mediated immunotherapy ...

IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m 2 administered intraperitoneally weekly) plus neoadjuvant and ...

IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.